DE69735949D1 - Zusammensetzung geeignet zur behandlung der pferdelahmheit - Google Patents
Zusammensetzung geeignet zur behandlung der pferdelahmheitInfo
- Publication number
- DE69735949D1 DE69735949D1 DE69735949T DE69735949T DE69735949D1 DE 69735949 D1 DE69735949 D1 DE 69735949D1 DE 69735949 T DE69735949 T DE 69735949T DE 69735949 T DE69735949 T DE 69735949T DE 69735949 D1 DE69735949 D1 DE 69735949D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- milf
- horse
- composition suitable
- donor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/295—Iron group metal compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US752415 | 1996-11-19 | ||
US08/752,415 US5891472A (en) | 1996-11-19 | 1996-11-19 | Treatment of equine laminitis |
PCT/US1997/020668 WO1998022090A1 (en) | 1996-11-19 | 1997-11-17 | Treatment of equine laminitis |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69735949D1 true DE69735949D1 (de) | 2006-06-29 |
DE69735949T2 DE69735949T2 (de) | 2007-01-04 |
Family
ID=25026227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69735949T Expired - Fee Related DE69735949T2 (de) | 1996-11-19 | 1997-11-17 | Zusammensetzung geeignet zur behandlung der pferdelahmheit |
Country Status (10)
Country | Link |
---|---|
US (3) | US5891472A (de) |
EP (1) | EP0946147B1 (de) |
JP (1) | JP2001509136A (de) |
AT (1) | ATE326948T1 (de) |
AU (1) | AU5435998A (de) |
BR (1) | BR9714573A (de) |
CA (1) | CA2273183A1 (de) |
DE (1) | DE69735949T2 (de) |
ES (1) | ES2263182T3 (de) |
WO (1) | WO1998022090A1 (de) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020048596A1 (en) * | 1994-12-30 | 2002-04-25 | Gregor Cevc | Preparation for the transport of an active substance across barriers |
US6479074B2 (en) | 1996-10-24 | 2002-11-12 | Pharmaceutical Applications Associates Llc | Methods and transdermal compositions for pain relief |
US5891472A (en) * | 1996-11-19 | 1999-04-06 | Meri Charmyne Russell | Treatment of equine laminitis |
US7629384B2 (en) * | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
US7914814B2 (en) * | 1997-09-17 | 2011-03-29 | Strategic Science & Technologies, Llc | Topical delivery of arginine of cause beneficial effects |
US6306383B1 (en) * | 1998-09-16 | 2001-10-23 | Wilson T Crandall | Method for topical treatment of scars with protein kinase C inhibitors |
HUP0102741A3 (en) * | 1998-10-23 | 2002-12-28 | Idea Ag | Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates |
SI1031347T1 (en) | 1999-01-27 | 2002-10-31 | Idea Ag | Transnasal transport/immunisation with highly adaptable carriers |
PT1031346E (pt) | 1999-01-27 | 2002-09-30 | Idea Ag | Vacinacao nao invasiva atraves da pele |
WO2001001962A1 (en) * | 1999-07-05 | 2001-01-11 | Idea Ag. | A method for the improvement of transport across adaptable semi-permeable barriers |
CA2414941C (en) | 2000-08-11 | 2010-12-14 | David R. Whitlock | Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same |
JP2002136025A (ja) * | 2000-10-26 | 2002-05-10 | Mitsubishi Electric Corp | 電磁機器 |
US6780849B2 (en) | 2000-12-21 | 2004-08-24 | Scimed Life Systems, Inc. | Lipid-based nitric oxide donors |
US6833139B1 (en) * | 2002-01-09 | 2004-12-21 | Ferndale Laboratories, Inc. | Composition and method for the treatment of anorectal disorders |
AU2003222569A1 (en) * | 2002-01-11 | 2003-07-24 | Whitlock, David R. | Compositions including ammonia oxidizing bacteria and methods of using same |
US20040018237A1 (en) | 2002-05-31 | 2004-01-29 | Perricone Nicholas V. | Topical drug delivery using phosphatidylcholine |
US20040092819A1 (en) * | 2002-08-16 | 2004-05-13 | Hmt High Medical Technologies Ag | Method for treating laminitis in horses, ponies and other equines with acoustic waves |
US20040105881A1 (en) * | 2002-10-11 | 2004-06-03 | Gregor Cevc | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
US6936273B2 (en) * | 2002-12-20 | 2005-08-30 | Idexx Laboratories, Inc. | Liposomal analgesic formulation and use |
WO2005030147A2 (en) * | 2003-09-26 | 2005-04-07 | Whitlock David R | Methods of using ammonia oxidizing bacteria |
JP5376761B2 (ja) * | 2004-02-23 | 2013-12-25 | ストラテジック サイエンス アンド テクノロジーズ, エルエルシー | 身体の外観および皮膚の外観を改善するための、一酸化窒素の局所送達 |
US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US20110028548A1 (en) * | 2004-04-19 | 2011-02-03 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US20090105336A1 (en) * | 2004-04-19 | 2009-04-23 | Strategic Science & Technologies, Llc | Beneficial Effects of Increasing Local Blood Flow |
WO2005102282A1 (en) * | 2004-04-19 | 2005-11-03 | Strategic Science & Technologies, Llc | Transdermal delivery of beneficial substances effected by a hostile biophysical environment |
US7740875B2 (en) * | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US20060078580A1 (en) * | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
KR20070086045A (ko) * | 2004-11-12 | 2007-08-27 | 이데아 아게 | 피부 상태 치료에서의 확대된 표면 집합체 |
JP2008520694A (ja) * | 2004-11-17 | 2008-06-19 | リンジー・バークソン | 非治癒性及び治癒遅延性の創傷及び潰瘍の治癒を促進させる組成物及び方法 |
US7731993B2 (en) * | 2004-11-17 | 2010-06-08 | Lindsey Berkson | Composition for treating a dermal anomaly |
US20090214618A1 (en) | 2005-05-27 | 2009-08-27 | Schoenfisch Mark H | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
US7744928B2 (en) * | 2006-04-14 | 2010-06-29 | Advanced Cardiovascular Systems, Inc. | Methods and compositions for treatment of lesioned sites of body vessels |
US8221690B2 (en) | 2007-10-30 | 2012-07-17 | The Invention Science Fund I, Llc | Systems and devices that utilize photolyzable nitric oxide donors |
US20090112197A1 (en) | 2007-10-30 | 2009-04-30 | Searete Llc | Devices configured to facilitate release of nitric oxide |
US7862598B2 (en) | 2007-10-30 | 2011-01-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
US8642093B2 (en) | 2007-10-30 | 2014-02-04 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
US20100292280A1 (en) * | 2007-04-15 | 2010-11-18 | Oron Zachar | Anti-pyretic vasodilators |
US8877508B2 (en) | 2007-10-30 | 2014-11-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
US10080823B2 (en) | 2007-10-30 | 2018-09-25 | Gearbox Llc | Substrates for nitric oxide releasing devices |
US8349262B2 (en) | 2007-10-30 | 2013-01-08 | The Invention Science Fund I, Llc | Nitric oxide permeable housings |
US7897399B2 (en) | 2007-10-30 | 2011-03-01 | The Invention Science Fund I, Llc | Nitric oxide sensors and systems |
US8980332B2 (en) | 2007-10-30 | 2015-03-17 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
EP2889028A1 (de) * | 2008-06-24 | 2015-07-01 | Intervet International B.V. | Transdermale pharmazeutische Zusammensetzung und Verfahren zur Behandlung von Entzündungen bei Rindern |
US20100227895A1 (en) * | 2009-03-05 | 2010-09-09 | Mpco- The Magic Powder Company | Method for treating equine laminitis |
EP2445493A1 (de) | 2009-06-24 | 2012-05-02 | Strategic Science & Technologies, LLC | Topische zusammensetzung mit naproxen |
US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
RU2505291C2 (ru) | 2009-06-24 | 2014-01-27 | СТРАТЕДЖИК САЙЕНС ЭНД ТЕКНОЛОДЖИЗ, ЭлЭлСи | Топическая композиция, содержащая ибупрофен |
EP4249001A3 (de) | 2009-08-21 | 2023-11-29 | Novan, Inc. | Topische gele |
WO2011022680A2 (en) | 2009-08-21 | 2011-02-24 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
JP2014501283A (ja) | 2010-12-29 | 2014-01-20 | ストラテジック サイエンス アンド テクノロジーズ, エルエルシー | アレルギーおよび他の適応症の処置のためのシステムおよび方法 |
ES2811515T3 (es) | 2010-12-29 | 2021-03-12 | Strategic Science & Tech Llc | Tratamiento de disfunción eréctil y otras indicaciones |
WO2012118819A2 (en) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same |
CA2830298C (en) * | 2011-03-17 | 2016-08-16 | Transdermal Biotechnology, Inc. | Topical nitric oxide systems comprising lecithin and methods of use thereof |
US8871254B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
US8871256B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
US8871259B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Techniques and systems for treatment of neuropathic pain and other indications |
US8871255B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment of skin and soft tissue infection with nitric oxide |
US8871258B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment and prevention of learning and memory disorders |
US8871260B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and compositions for muscular and neuromuscular diseases |
US8871257B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery |
US8871262B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Compositions and methods for treatment of osteoporosis and other indications |
US8871261B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Cancer treatments and compositions for use thereof |
US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
WO2014163030A1 (ja) | 2013-04-01 | 2014-10-09 | 第一三共株式会社 | 馬の炎症治療のための製剤 |
US10517817B2 (en) | 2013-05-09 | 2019-12-31 | Syk Technologies, Llc | Deep topical systemic nitric oxide therapy apparatus and method |
KR20230165365A (ko) | 2014-04-15 | 2023-12-05 | 에이오바이오미 엘엘씨 | 암모니아-산화 니트로소모나스 유트로파 균주 d23 |
US11225640B2 (en) | 2014-04-15 | 2022-01-18 | Aobiome Llc | Ammonia oxidizing bacteria for treatment of psoriasis |
WO2017132275A1 (en) | 2016-01-27 | 2017-08-03 | Syk Technologies, Llc | Nitric oxide topical application apparatus and methods |
CN110225746A (zh) * | 2016-11-09 | 2019-09-10 | 普罗维塔欧洲技术有限公司 | 用于治疗兽蹄感染的抗微生物制剂 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2440371A1 (fr) * | 1978-10-31 | 1980-05-30 | Fisons Ltd | Nouveaux composes azotes heterocycliques, des compositions pharmaceutiques en contenant et des procedes pour les preparer |
IE54286B1 (en) * | 1983-01-18 | 1989-08-16 | Elan Corp Plc | Drug delivery device |
CA1319886C (en) * | 1987-02-03 | 1993-07-06 | Alberto Ferro | Mixed micelle solutions |
CH681427A5 (de) * | 1987-07-01 | 1993-03-31 | Zambon Spa | |
CH680223A5 (de) * | 1989-07-17 | 1992-07-15 | Pier Luigi Prof Dr Luisi | |
DE4305881C1 (de) * | 1993-02-26 | 1994-03-03 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit Wirkstoffen, welche Stichoxid-Quellen darstellen, Verfahren zu seiner Herstellung sowie seine Verwendung |
AU7655494A (en) * | 1993-08-28 | 1995-03-22 | University Of Sheffield, The | Treatment of laminitis |
GB2292520B (en) * | 1994-08-25 | 1998-09-02 | Univ Sheffield | Transdermal dressings for animals |
US5543430A (en) * | 1994-10-05 | 1996-08-06 | Kaesemeyer; W. H. | Method and formulation of stimulating nitric oxide synthesis |
US5891472A (en) * | 1996-11-19 | 1999-04-06 | Meri Charmyne Russell | Treatment of equine laminitis |
-
1996
- 1996-11-19 US US08/752,415 patent/US5891472A/en not_active Expired - Fee Related
-
1997
- 1997-08-19 US US08/914,230 patent/US6045827A/en not_active Expired - Fee Related
- 1997-11-17 ES ES97948262T patent/ES2263182T3/es not_active Expired - Lifetime
- 1997-11-17 BR BR9714573-4A patent/BR9714573A/pt unknown
- 1997-11-17 DE DE69735949T patent/DE69735949T2/de not_active Expired - Fee Related
- 1997-11-17 AU AU54359/98A patent/AU5435998A/en not_active Abandoned
- 1997-11-17 CA CA002273183A patent/CA2273183A1/en not_active Abandoned
- 1997-11-17 AT AT97948262T patent/ATE326948T1/de not_active IP Right Cessation
- 1997-11-17 WO PCT/US1997/020668 patent/WO1998022090A1/en active IP Right Grant
- 1997-11-17 EP EP97948262A patent/EP0946147B1/de not_active Expired - Lifetime
- 1997-11-17 JP JP51979898A patent/JP2001509136A/ja not_active Withdrawn
-
1999
- 1999-06-16 US US09/333,974 patent/US6287601B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE326948T1 (de) | 2006-06-15 |
EP0946147A1 (de) | 1999-10-06 |
WO1998022090A1 (en) | 1998-05-28 |
BR9714573A (pt) | 2002-07-23 |
US6045827A (en) | 2000-04-04 |
EP0946147A4 (de) | 2001-12-12 |
US5891472A (en) | 1999-04-06 |
AU5435998A (en) | 1998-06-10 |
EP0946147B1 (de) | 2006-05-24 |
JP2001509136A (ja) | 2001-07-10 |
US6287601B1 (en) | 2001-09-11 |
ES2263182T3 (es) | 2006-12-01 |
DE69735949T2 (de) | 2007-01-04 |
CA2273183A1 (en) | 1998-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69735949D1 (de) | Zusammensetzung geeignet zur behandlung der pferdelahmheit | |
ATE383169T1 (de) | Komponente und zusammensetzungen zur verabreichung von wirkstoffen | |
DE69703294D1 (de) | Zusammensetzungen die konjugate von cis-docosahexaenoic-säure und taxotere enthalten | |
SI0882021T1 (en) | New phenanthridines | |
TR27992A (tr) | Suda veya alkolde cözünebilen veya dagilabilen silikon asili termoplastik elastomerik kopolimerler ve bunlari iceren sac ve cilt bakim bilesimleri. | |
BR9507730A (pt) | Uso de formulações em gel como composições de tratamento | |
PT1039912E (pt) | Agentes angiostaticos e composicoes para tratar glaucoma glc1a | |
MX9306295A (es) | Composiciones farmaceuticas para tratar sintomas de resfriado. | |
DE69922684D1 (de) | Verwendung von 2-methoxyestradiol als fungizide | |
PT969843E (pt) | Composicoes antitussicas contendo teobromina | |
DE69109115T2 (de) | Verfahren zur behandlung der alopezie. | |
KR970703762A (ko) | N- 아세틸- l- 시스테인을 포함하는 국소용 조성물(topical compositions comprising n-acetyl-l-cysteine) | |
ES2104133T3 (es) | Composiciones cosmeticas o farmaceuticas que contienen glicerofosfolipidos desacilados para uso topico. | |
ATE541565T1 (de) | Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus | |
CA2408541A1 (en) | Treating eczema and/or psoriasis | |
TR199701520T1 (xx) | Ac�n�n iyile�tirilmesi i�in analjesik bile�ikleri �reten h�cre soyu. | |
FR2825273B1 (fr) | Composition pour le traitement des signes cutanes du vieillissement | |
EP1210937A3 (de) | Vorrichtung zur topischen Behandlung von Akne und Verfahren zu deren Herstellung | |
PT920336E (pt) | Pesticidas que compreendem alcaloides da benzofenantridina | |
DE69526584T2 (de) | Verwendung von immunosuppressiva zur behandlung der schizophrenie | |
DK227090D0 (da) | Organisk guldkompleks til topisk anvendelse | |
DE69426986D1 (de) | Behandlung von laminitis | |
DK1135239T3 (da) | Formuleringer til trækonservering | |
DE69424679D1 (de) | Zusammensetzung zur behandlung oder vorbeugung von herpes | |
ATE338768T1 (de) | Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |